Chemomab Therapeutics Ltd. Files 6-K, Details Former Names
Ticker: CMMB · Form: 6-K · Filed: Jul 25, 2024 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $1.235, $0.0001, $10.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-history, filing, foreign-private-issuer
TL;DR
Chemomab (formerly Anchiano/BioCancell) filed a 6-K on 7/25/24, showing historical name changes.
AI Summary
Chemomab Therapeutics Ltd. filed a Form 6-K on July 25, 2024, reporting information as a foreign private issuer. The filing indicates the company was formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., with name changes occurring in 2018 and 2011, respectively. The company is based in Tel Aviv, Israel, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides historical context for Chemomab Therapeutics Ltd., clarifying its previous corporate identities and the timeline of these changes, which can be important for understanding its corporate evolution.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of historical information and does not contain new financial or operational risks.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Filer
- Anchiano Therapeutics Ltd. (company) — Former Company Name
- BioCancell Ltd. (company) — Former Company Name
- 20180906 (date) — Date of name change from Anchiano Therapeutics Ltd.
- 20111104 (date) — Date of name change from BioCancell Ltd.
- 20240725 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, providing information to the SEC.
When was Chemomab Therapeutics Ltd. formerly known as Anchiano Therapeutics Ltd. and when did that name change occur?
Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd., and the date of that name change was September 6, 2018 (20180906).
When was Chemomab Therapeutics Ltd. formerly known as BioCancell Ltd. and when did that name change occur?
Chemomab Therapeutics Ltd. was formerly known as BioCancell Ltd., and the date of that name change was November 4, 2011 (20111104).
What is the Standard Industrial Classification (SIC) code for Chemomab Therapeutics Ltd.?
The Standard Industrial Classification code for Chemomab Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Where is Chemomab Therapeutics Ltd. located?
Chemomab Therapeutics Ltd. is located in Tel Aviv, Israel, with its business and mailing address at Kiryat Atidim, Building 7, Tel Aviv, L3, 6158002.
Filing Stats: 1,527 words · 6 min read · ~5 pages · Grade level 16.3 · Accepted 2024-07-25 08:09:40
Key Financial Figures
- $1.235 — value per share, at a purchase price of $1.235 per share; and (ii), in lieu of ADSs, p
- $0.0001 — Warrants will have an exercise price of $0.0001 per ADS, be immediately exercisable and
- $10.0 million — the Private Placement of approximately $10.0 million before deducting any offering expenses
Filing Documents
- zk2431711.htm (6-K) — 29KB
- exhibit_99-1.htm (EX-99.1) — 34KB
- exhibit_99-2.htm (EX-99.2) — 41KB
- exhibit_99-3.htm (EX-99.3) — 248KB
- exhibit_99-4.htm (EX-99.4) — 143KB
- exhibit_99-5.htm (EX-99.5) — 93KB
- exhibit_99-6.htm (EX-99.6) — 14KB
- exhibit_99-2slide1.jpg (GRAPHIC) — 60KB
- exhibit_99-2slide2.jpg (GRAPHIC) — 304KB
- exhibit_99-2slide3.jpg (GRAPHIC) — 149KB
- exhibit_99-2slide4.jpg (GRAPHIC) — 189KB
- exhibit_99-2slide5.jpg (GRAPHIC) — 180KB
- exhibit_99-2slide6.jpg (GRAPHIC) — 85KB
- exhibit_99-2slide7.jpg (GRAPHIC) — 174KB
- exhibit_99-2slide8.jpg (GRAPHIC) — 178KB
- exhibit_99-2slide9.jpg (GRAPHIC) — 160KB
- exhibit_99-2slide10.jpg (GRAPHIC) — 175KB
- exhibit_99-2slide11.jpg (GRAPHIC) — 58KB
- exhibit_99-2slide12.jpg (GRAPHIC) — 101KB
- exhibit_99-2slide13.jpg (GRAPHIC) — 148KB
- exhibit_99-2slide14.jpg (GRAPHIC) — 138KB
- exhibit_99-2slide15.jpg (GRAPHIC) — 136KB
- exhibit_99-2slide16.jpg (GRAPHIC) — 103KB
- exhibit_99-2slide17.jpg (GRAPHIC) — 112KB
- exhibit_99-2slide18.jpg (GRAPHIC) — 131KB
- exhibit_99-2slide19.jpg (GRAPHIC) — 124KB
- exhibit_99-2slide20.jpg (GRAPHIC) — 149KB
- image0.jpg (GRAPHIC) — 69KB
- image1.jpg (GRAPHIC) — 175KB
- image2.jpg (GRAPHIC) — 103KB
- 0001178913-24-002290.txt ( ) — 5016KB
Forward-Looking Statements
Forward-Looking Statements This Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this Report other than statements of historical facts are "forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this Report include, but are not limited to, statements regarding: the use of proceeds and timing and consummation of the Private Placement; the satisfaction of customary closing conditions with respect to the Private Placement; the cash runway of the Company; the Company's clinical development activities and timelines for CM-101; the timing and future occurrence of other clinical and clinical activities including proposed clinical trial enrollment and the Company's plans and timing to advance CM-101 into Phase 3; and the expected clinical benefits of CM-101 and potential to produce clinically meaningful outcomes in patients with primary sclerosing cholangitis. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this Report. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: preliminary or topline results are based on a preliminary analysis of key efficacy and safety data; the potential that success in preclinical testing and earlier clinical trials does not